RNA-Based Therapeutics and Vaccines Summit Asia

Welcome to the Inaugural RNA-Based Therapeutics and Vaccines Summit Asia

Uniting RNA Therapeutic and Vaccine Developers from Across Asia

Asia is booming in RNA innovation and partnerships towards commercial markets following key investments from the Korea Disease Control and Prevention Agency (KDCA) to fight future disease outbreaks and China’s race towards the first RNA-based cancer vaccine, rapidly gaining global attention.

In response to this momentum, the inaugural RNA-Based Therapeutics and Vaccines Summit Asia launches in South Korea to offer the most comprehensive industry dedicated platform to connect Asia’s thriving RNA biopharma community with groundbreaking mRNA, sa-RNA, circular RNA and siRNA modalities and strategic insights to fast-track pipelines into the clinical and beyond.

Showcasing the industry’s innovations and scientific progress in emerging health threats, personalized cancer vaccines and rare diseases, with brand new never-before-seen data, covering the end-to-end from discovery through to manufacturing and commercial success.

Join 80+ key RNA experts from South Korea, China, Japan, Singapore and beyond, for an unrivalled learning and networking opportunity to develop the next generation of efficacious and safe RNA medicines for patients faster.


URLs:
Website: https://go.evvnt.com/3155275-2?pid=2874
Brochure: https://go.evvnt.com/3155275-3?pid=2874

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Prices:
Drug Developer Pricing - Conference Only: USD 1749.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 1949.00,
Drug Developer Pricing - Conference + 2 Workshops: USD 2149.00,
Academic Pricing - Conference Only: USD 1549.00,
Academic Pricing - Conference + 1 Workshop: USD 1699.00,
Academic Pricing - Conference + 2 Workshops: USD 1849.00,
Solution Provider Pricing - Conference Only: USD 3799.00,
Solution Provider Pricing - Conference + 1 Workshop: USD 4448.00,
Solution Provider Pricing - Conference + 2 Workshops: USD 5097.00

Speakers: Bo Ying Chief Executive Officer AboGen Inc., Kevin Kee-Jong Hong Professor Gachon University, Adam zhao Chief Executive Officer AnlongBio, Elle Li R AND D Director Innorna Co. Ltd, Hayato Watanabe President and Chief Executive Officer Crafton Biotechnology, Hyukjin Lee Professor Seoul National University, Jaehyun Choi Chief Executive Officer and Head of R AND D Genexine, Inc., June Kim CMC Lead CEPI, Madhavan Nallani Founder and Chief Executive Officer ACM Biosciences, Norihiko Shiraishi Executive Officer, Chief Scientific Officer and mRNA IPG Unit Head NANO MRNA Co., Ltd., Pengbo Guo Partner CybernaX Bio, Rongkuan Frank Hu Chief Executive Officer Starna therapeutics, Sang Hwan Seo Director International Vaccine Institute (IVI), Sunghoon Ma Head of the Medicine Discovery and Development Division GC Pharma, Swarnendu Kaviraj Associate Director of R AND D Gennova Biopharma Limited, Wonil Kim Chief Scientific Officer Aston Science Inc, Xian Zeng Chief Executive Officer and Co-Founder Byterna Therapeutics, Xiangrong Song Chief Executive Officer and Co-Founder WestGene Biopharma, Xueliang Yu Vice President Starna Therapeutics, Yaoqi Zhou Professor Shenzen Bay Laboratory, Yasumasa Ota mRNA technology Leader Meiji Seika Pharma, Yeong-Chan Ahn Business Development Director sml biopharm, Yi Yan Yang Distinguished Principal Scientist Agency for Science, Technology and Research (A*STAR), Yu Pang Senior Scientist Pfizer